Ozempic vs Wegovy: Which is Better for Weight Loss?

Many Canadians exploring GLP-1 medications for weight loss struggle to understand the difference between Ozempic and Wegovy. Both medications contain the same active ingredient—semaglutide—but they differ in dosing, approved uses, and cost. This confusion stems from a regulatory distinction that makes one drug a diabetes medication (Ozempic) and the other a dedicated obesity treatment (Wegovy).

Understanding which medication is right for you requires looking beyond the shared active ingredient. The dosing is different, the Health Canada approvals are different, and what your insurance might cover varies significantly. This guide breaks down the distinctions that actually matter for your weight loss goals.

Quick Comparison

Key Differences Between Ozempic and Wegovy

Both Ozempic and Wegovy contain semaglutide, a GLP-1 receptor agonist administered as once-weekly subcutaneous injections. However, three critical differences determine which medication is appropriate for you.

Approved Uses

Ozempic received Health Canada approval for type 2 diabetes management. Weight loss is a documented effect, not the primary indication. Wegovy, by contrast, is approved specifically for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition like hypertension or dyslipidemia.

This distinction directly affects prescribing practices and insurance coverage across Canada. Off-label prescribing—when your doctor prescribes Ozempic for weight loss even though Health Canada only approved it for diabetes—is legal and common, but insurance coverage is less predictable.

Dosing and Strength

Ozempic maxes out at 2 mg per week for diabetes control. Wegovy goes up to 2.4 mg per week, the dose used in the major weight loss trials. While 0.4 mg seems small, clinical trials specifically tested the 2.4 mg dose for weight loss, and it consistently produced better outcomes than lower doses.

Both medications require gradual dose escalation over 16-20 weeks to minimize side effects. You'll start at 0.25 mg weekly and increase slowly. This means you won't reach the full therapeutic dose—and maximum weight loss effects—for several months.

How Semaglutide Works

Semaglutide mimics GLP-1 (glucagon-like peptide-1), a hormone your intestines release after eating. By activating GLP-1 receptors throughout your body, it reduces appetite signals to your brain, slows stomach emptying so you feel fuller longer, and improves how your body regulates blood sugar. Whether the pen says Ozempic or Wegovy, the molecule doing the work is identical—the difference is how much of it you're getting.

Clinical Evidence: What the Studies Show

The research clearly demonstrates that these medications were tested for different purposes, with different populations, producing different results.

Wegovy's Weight Loss Results

The STEP trials evaluated semaglutide 2.4 mg (Wegovy's dose) specifically for weight loss in adults without diabetes. In the STEP 1 trial, participants lost an average of 14.9% of their body weight over 68 weeks compared to 2.4% with placebo (1). For a 200-pound person, 15% weight loss means losing 30 pounds—roughly one pound every two weeks on average.

When combined with intensive behavioral therapy in the STEP 3 trial, the average weight loss reached 16% of body weight (3). The STEP 4 trial demonstrated that continuing Wegovy after initial weight loss maintained those results, while stopping the medication led to significant weight regain (4).

Ozempic's Weight Loss Data

Ozempic at its maximum 2 mg dose produces meaningful weight loss, but the trials focused on glycemic control in people with type 2 diabetes. In diabetes trials lasting approximately 40-68 weeks, Ozempic at 2 mg produced average weight loss of 6-7 kg. However, direct comparison is difficult because these trials enrolled people with type 2 diabetes specifically, not for weight loss as a primary goal.

How Semaglutide Compares to Other GLP-1s

The STEP 8 trial directly compared semaglutide 2.4 mg (Wegovy) to liraglutide 3 mg (Saxenda), another GLP-1 medication. Semaglutide delivered significantly more weight loss: 15.8% versus 6.4% of body weight (2). While this wasn't specifically Ozempic, it demonstrates that higher semaglutide doses drive better weight loss outcomes.

Understanding Side Effects

Both medications cause similar side effects because they contain the same active ingredient. The most common issues are gastrointestinal: nausea, diarrhea, constipation, and occasional vomiting, especially during dose escalation.

What to Expect

Most people experience side effects during the first few weeks after starting or increasing their dose. These symptoms typically peak within the first few days of a new dose level and improve as your body adjusts. The severity correlates with dose, so Wegovy's 2.4 mg may produce slightly more GI upset than Ozempic's 2 mg, but the difference is marginal for most people.

Managing Common Side Effects

To minimize discomfort:

• Eat smaller, more frequent meals
• Avoid high-fat, greasy, or spicy foods
• Stay well-hydrated
• Take your injection on the same day each week
• Don't skip the gradual dose escalation

When to Contact Your Doctor

Seek medical attention if you experience:

• Severe, persistent abdominal pain (possible pancreatitis)
• Persistent nausea or vomiting that prevents you from keeping down food or fluids
• Signs of gallbladder problems (pain in the upper right abdomen, fever, yellowing of skin or eyes)
• Symptoms of thyroid tumors (lump in neck, hoarseness, difficulty swallowing)

While serious side effects like pancreatitis and gallbladder issues are rare, they require prompt medical evaluation. Both medications carry similar risk profiles for these serious but uncommon complications.

Which One Is Right for You?

The "better" drug depends entirely on your medical profile, financial situation, and what's available at your pharmacy.

If you have type 2 diabetes and need to lose weight: Ozempic addresses both issues, and your insurance is more likely to cover it without extensive documentation.

If your primary goal is weight loss and you don't have diabetes: Wegovy is the evidence-based choice. The 2.4 mg dose is what the obesity trials used, and the results from those trials are superior (1)(3)(4).

If Wegovy is unavailable or unaffordable: Ozempic prescribed off-label at 2 mg weekly is a reasonable alternative. You'll likely see meaningful weight loss, just potentially less than the full Wegovy dose. Individual response varies, and the difference between 2 mg and 2.4 mg may not be clinically significant for everyone.

If cost is a major barrier: Shop around at different Canadian pharmacies, as prices can vary. Some Canadian online clinics offer competitive pricing or payment plans. Ask your doctor about all available options.

Special Considerations

Adolescent Use

Wegovy is approved for adolescents aged 12 and older with obesity in some jurisdictions. The adolescent STEP trial showed an average 16.1% body weight reduction over 68 weeks (5). Ozempic does not have this indication. If you're a parent exploring options for a teenager, Wegovy is the only evidence-based semaglutide choice with regulatory approval for this age group.

Availability in Canada

Wegovy availability has been inconsistent across Canadian pharmacies. Supply issues mean that even with a prescription and insurance coverage, you may face delays. If Wegovy is unavailable in your area, discuss with your doctor whether starting Ozempic off-label is appropriate while you wait.

Cost and Insurance Guide

As of early 2024, both medications have similar list prices in Canada, ranging from $400 to $450 per month, though prices vary by pharmacy. However, coverage differs significantly.

Understanding Your Coverage

Private insurance plans more readily cover Ozempic because it's approved for diabetes treatment. Coverage for weight loss alone is less common but varies by insurer. Public provincial drug plans typically don't cover either medication for weight loss without diabetes.

Example scenario: If your private insurance covers Ozempic for diabetes at 80%, you'd pay roughly $80-90 per month out of pocket. But if you're using it off-label for weight loss without diabetes, you might receive no coverage, putting your monthly cost at $400+. Always get pre-authorization in writing before starting treatment.

Questions to Ask Your Insurer

Before filling your prescription:

• Is GLP-1 medication covered for weight management without diabetes?
• What documentation does my doctor need to provide?
• Is prior authorization required?
• What's my copay or coinsurance percentage?
• Are there any restrictions on dose or duration?

Maximizing Your Results

Clinical trial participants who achieved the best results combined medication with comprehensive lifestyle changes. The STEP 3 trial paired semaglutide with 500-calorie-per-day deficits and regular exercise (3). Participants who relied solely on the injection without behavioral modification still lost weight, but significantly less.

Nutrition Strategies

Consider working with a registered dietitian to:

• Create a sustainable calorie deficit
• Focus on protein-rich foods that promote satiety
• Plan meals that align with reduced appetite
• Navigate social eating situations

Physical Activity

Regular movement enhances weight loss and helps maintain muscle mass during weight reduction. Start with activities you enjoy and can sustain long-term, gradually increasing intensity and duration as your fitness improves.

Habit Tracking

Consider using a meal planning app or food journal to track your habits alongside medication. Monitoring patterns helps you identify what works and adjust strategies as needed.

Key Takeaways

Ozempic and Wegovy contain the same active ingredient but serve different purposes. Wegovy is dosed higher (2.4 mg versus 2 mg) and purpose-built for weight loss, delivering superior results in clinical trials specifically designed for obesity treatment. Ozempic works for weight loss too, but it's capped at a lower dose and approved for diabetes management.

Your choice depends on your diagnosis, insurance coverage, and pharmacy availability. If you're pursuing weight loss and Wegovy is accessible and affordable, it's the evidence-based choice. If not, Ozempic prescribed off-label at 2 mg weekly is a solid alternative that many Canadians use successfully.

Remember that medication is one component of comprehensive weight management. Success requires a combination of pharmacotherapy, nutrition changes, physical activity, and behavioral strategies.

Next Steps

Before your next healthcare appointment:

• Check your insurance coverage for both medications
• Calculate potential out-of-pocket costs using your specific plan details
• Prepare questions about which medication best fits your medical history
• Consider what lifestyle changes you're ready to implement alongside medication
• Research pharmacy availability in your area

Work with your healthcare provider to create a comprehensive plan tailored to your individual needs, goals, and circumstances.

Sources

• Once-Weekly Semaglutide in Adults with Overweight or Obesity.
• Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
• Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
• Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
• Once-Weekly Semaglutide in Adolescents with Obesity.